NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
Trading expected to continue under ticker symbol 'NKGN' for common stock and 'NKGNW' for warrants.
NKGen Biotech, Inc. ('NKGen' or the 'Company') has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025; and intends to continue complying with all Securities and Exchange ('SEC') reporting requirements.
The Company has cancelled its previously announced 1-for-6 reverse stock split.
Enrollment in randomized Phase 2a Alzheimer's trial is expected to be completed by the end of Q2 with an initial readout planned for later in 2025.
SANTA ANA, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, today announced that on March 3, 2025 it received notice that the Nasdaq Hearings Panel determined to delist the Company's common stock from the Nasdaq Global Market after the close of trading on March 4, 2025, solely due to the Company's continued failure to comply with Rule 5450(b)(2)(A) of Nasdaq's Listing Requirements, related to the market value of its common stock. After delisting from Nasdaq, the Company expects that the common stock will be traded on a market operated by the OTC Markets Group, Inc. commencing on March 5, 2025. The Company intends to apply to trade on the OTCQX platform, the highest OTC tier, which requires ongoing compliance with SEC public reporting requirements. After initial trading on OTC Pink in a short transition period, NKGen's common stock and warrants are expected to begin trading on the OTCQX platform under the same ticker symbols, 'NKGN' for shares of common stock and 'NKGNW' for warrants.
With the move away from Nasdaq and its minimum bid price requirement, the Company will not implement the previously announced 1-for-6 reverse stock split.
'Our Company has navigated significant challenges this past year, mostly related to the financial restructuring of our former parent company in South Korea, NKMAX, Co. Ltd.,' said Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen. 'Despite these obstacles, our science and clinical data have remained a consistent source of strength. While initially met with skepticism, our innovative approach using one's own enhanced NK cells to improve proteins and reduce neuroinflammation in Alzheimer's patients and other neurodegenerative diseases has gained significant traction. We've presented promising data at major Alzheimer's focused medical conferences, Alzheimer's Association International Conference (AAIC) and Clinical Trials on Alzheimer's Disease (CTAD) in 2024, received U.S. FDA Fast Track designation, published our Phase 1 results in Alzheimer's Research & Therapy, and attracted growing interest and support. We continue to work on funding the business to support our Phase 2 clinical trial, with the goal of achieving the necessary data and milestones towards obtaining accelerated approval. We remain intently focused on completing enrollment in our randomized Phase 2a Alzheimer's clinical trial with an expected preliminary readout by year-end, and we look forward to resuming trading on Nasdaq once we are able to meet the necessary listing requirements and apply again.'
NKGen Interim Chief Financial Officer James Graf added, 'We look forward to continued support from our stockholders and active liquidity in our shares trading on the OTC Markets until we can re-list on Nasdaq. We do not expect this transition to materially affect our ongoing financing discussions, especially as we intend to maintain SEC reporting obligations and do not have to proceed with the previously announced reverse stock split.'
About NKGen BiotechNKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.
Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at www.sec.gov and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Internal Contact:Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@nkgenbiotech.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Bentley Earnings: What To Look For From BSY
Infrastructure design software provider Bentley Systems (NASDAQ:BSY) will be reporting results this Wednesday morning. Here's what investors should know. Bentley beat analysts' revenue expectations by 1.4% last quarter, reporting revenues of $370.5 million, up 9.7% year on year. It was a very strong quarter for the company, with a solid beat of analysts' EBITDA estimates and an impressive beat of analysts' billings estimates. Is Bentley a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Bentley's revenue to grow 10% year on year to $363.4 million, slowing from the 11.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.29 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bentley has missed Wall Street's revenue estimates four times over the last two years. Looking at Bentley's peers in the software-as-a-service segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Manhattan Associates delivered year-on-year revenue growth of 2.7%, beating analysts' expectations by 3.3%, and Palantir reported revenues up 48%, topping estimates by 6.8%. Manhattan Associates traded up 7% following the results. Read our full analysis of Manhattan Associates's results here and Palantir's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the software-as-a-service stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3% on average over the last month. Bentley is up 4.3% during the same time and is heading into earnings with an average analyst price target of $54.31 (compared to the current share price of $57.90). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Noodles (NDLS) To Report Earnings Tomorrow: Here Is What To Expect
Casual restaurant chain Noodles & Company (NASDAQ:NDLS) will be announcing earnings results this Wednesday afternoon. Here's what to expect. Noodles met analysts' revenue expectations last quarter, reporting revenues of $123.8 million, up 2% year on year. It was a slower quarter for the company, with a significant miss of analysts' EBITDA estimates and a significant miss of analysts' EPS estimates. Is Noodles a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Noodles's revenue to grow 3.5% year on year to $131.9 million, improving from the 1.8% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.06 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Noodles has missed Wall Street's revenue estimates six times over the last two years. Looking at Noodles's peers in the modern fast food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Shake Shack delivered year-on-year revenue growth of 12.6%, beating analysts' expectations by 0.9%, and Wingstop reported revenues up 12%, topping estimates by 0.5%. Shake Shack traded down 20.7% following the results while Wingstop was up 29.7%. Read our full analysis of Shake Shack's results here and Wingstop's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the modern fast food stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 6.3% on average over the last month. Noodles is up 14% during the same time and is heading into earnings with an average analyst price target of $2.83 (compared to the current share price of $0.90). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Earnings To Watch: Allient (ALNT) Reports Q2 Results Tomorrow
Precision motion systems specialist Allient (NASDAQ:ALNT) will be reporting results this Wednesday afternoon. Here's what to expect. Allient beat analysts' revenue expectations by 5.7% last quarter, reporting revenues of $132.8 million, down 9.5% year on year. It was an incredible quarter for the company, with a solid beat of analysts' EPS estimates and an impressive beat of analysts' EBITDA estimates. Is Allient a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Allient's revenue to decline 2.3% year on year to $132.9 million, improving from the 7.3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.47 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Allient has missed Wall Street's revenue estimates twice over the last two years. Looking at Allient's peers in the electronic components segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Bel Fuse delivered year-on-year revenue growth of 26.3%, beating analysts' expectations by 10.1%, and Littelfuse reported revenues up 9.8%, topping estimates by 6.8%. Bel Fuse traded up 18.8% following the results while Littelfuse was also up 9.1%. Read our full analysis of Bel Fuse's results here and Littelfuse's results here. Investors in the electronic components segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Allient is up 4.7% during the same time and is heading into earnings with an average analyst price target of $37.33 (compared to the current share price of $39.67). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
